Your session is about to expire
← Back to Search
Vigamox for Graft Versus Host Disease of the Eye
Study Summary
This trial is testing whether the antibiotic Vigamox can treat ocular GVHD. One eye of each patient will be treated with Vigamox, while the other eye will be treated with a placebo. The results will help determine if Vigamox can be used to treat ocular GVHD.
- Graft Versus Host Disease (GVHD) of the Eye
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 150 Patients • NCT02980523Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any similar investigations to the Vigamox study?
"As of right now, there are 26 Vigamox trials underway with 13 of them being in Phase 3. The hub for these studies appears to be Redwood City, California; however, there are 488 total study sites for Vigamox."
Are participants still being enrolled for this experiment?
"Presently, this clinical trial is seeking participants, as noted on clinicaltrials.gov. This research was initially posted on 6/15/2020, with the most recent update taking place on 1/12/2022."
What is the Vigamox FDA status?
"While Vigamox has not yet been proven effective, it has shown some promise in terms of safety, and thus received a score of 2."
Which eye conditions does Vigamox help to treat?
"Vigamox is most often prescribed to treat bacterial pink eye. Additionally, it can also be used as an ocular antibacterial, to prevent the plague, and to manage postoperative infections."
Share this study with friends
Copy Link
Messenger